All News
Emphasis that drug holiday is NOT drug retirement in osteoporosis. Ideal time to re-initiate is quite uncertain however. Continue to monitor DEXA and fracture risk factors.
@RheumNow #ACR22 #osteoporosis https://t.co/iLKrxdzpAR
Julian Segan JulianSegan ( View Tweet)
Valero et al. Combined biologics in PsA. @RheumNow #ACR22 Abstr1044 https://t.co/7nNf0Ktf0M https://t.co/CIE9BnBFvx
Richard Conway RichardPAConway ( View Tweet)
The Great Debate! Should you treat pre-clinical RA?
First - likelihood of RA?
If you have +ACPA or RF in sputum, there is 67% chance of developing clinical RA!
@RheumNow #ACR22 https://t.co/K7pUhvbEDR
Robert B Chao, MD doctorRBC ( View Tweet)
💠CYC confers a 27% risk of congenital malformations and ⬆️miscarriage rate
💠Contraception is recommended during use and 3 mos after tx
#ACR22 @Rheumnow https://t.co/A73vCMZdxd
sheila RHEUMarampa ( View Tweet)
Can we predict PsA incidence and prevalence trends?
Germany long-term projection 2040
3 scenarios:
1. increase 5%/yr
2. stable
3. decrease 5%/yr.
Best scenario (3) = peak diagnoses in 2028. Are medical resources ready for it?
https://t.co/ws87zDukuM
Abs#1019 #ACR22 @Rheumnow https://t.co/dqkfrag0w2
Aurelie Najm AurelieRheumo ( View Tweet)
Atypical femoral fracture risk increases over time. Risk decreases slowly as well with time off treatment. Absolute risk remains relatively low however.
@RheumNow #ACR22 #osteoporosis https://t.co/pcIfhRW4WJ
Julian Segan JulianSegan ( View Tweet)
💉COVID-19 vaccination in pregnant pts with rheumatic disease💉
🤰⬇️pre term births in vaccinated
🤰PPROM ⬆️ unvaccinated
✅More support 4 importance of covid vacc in our 🤰
Stellar work from covid GRA- Fantastic presentation by @Sineadm15 #ACR22 @RheumNow @RichardPAConway https://t.co/LLaLJSqS6W
Patricia Harkins DrTrishHarkins ( View Tweet)
Good BMD gains in switching BP->denosumab, especially in first few years. #sequentialtherapy
@RheumNow #ACR22 #osteoporosis https://t.co/t1hItKn8sB
Julian Segan JulianSegan ( View Tweet)
Most rheums round down on dosing because of the weight based recc's, but hydroxychloroquine dosing less than 5 Mg/kg/day leads to increased hospitalizations for #SLE flares abst#1654 #ACR22 #PressConference @rheumnow https://t.co/GGnnl14cy9
TheDaoIndex KDAO2011 ( View Tweet)
Phase 1 data shows Ebdarokimab (IL12/23i) safe and well tolerated in moderate to severe plaque psoriasis patients. Abs 0752 #ACR22 @RheumNow https://t.co/QqTE4WJtDa https://t.co/eMaEurZAr0
Dr. Rachel Tate uptoTate ( View Tweet)
The great debate
Next steps to develop RA prevention
Kevin Deane
“It’s time to move from disease modifying drugs to disease modifying therapeutic approaches”
#ACRdebate #ACR22 @RheumNow https://t.co/3vt58sXlDx
Aurelie Najm AurelieRheumo ( View Tweet)
Advancing Telemedicine in Rheumatology
'We all became Zoomatologists (Zheum-atologists?) since COVID.' -Jack Cush @RheumNow
@RheumNow #ACR22
Akhil Sood MD AkhilSoodMD ( View Tweet)
Pts w/ pre-existing rheumatic conditions 3.6 times likelier to new rheumatic disease features or worsening disease after starting ICI for melanoma, Abs 0756 #ACR22 @RheumNow https://t.co/s1f1QxmJzA https://t.co/6cKllBzqJn
Dr. Rachel Tate uptoTate ( View Tweet)
Osteoporotic fx in AS
Abstract #0388 #ACR22 @RheumNow
🦴2k adults in RISE, mean age 68y, 44% female, 76% white
🦴Higher risk with: older age, increased comorbidity index, OP history, chronic use of opioids, low BMI
🦴Men and women were equally likely to fracture
Catherine Sims, MD DrCassySims ( View Tweet)
Multiplex peripheral blood in 200+ ILD pts
Differences in IL-17 RD-ILD>IPF> IPAF
Higher IL-13 strongly asso w/ non-progression of ILD in RD-ILD, IPF & IPAF
OR 0.4
Almost surprising considering known profibrotic role of IL-13 🧐
https://t.co/21UMq6w9hI
Abs#1109 #ACR22 @Rheumnow https://t.co/7tfk74zH8A
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR22 Abstr#0826 2 years on since FDA approved #Tocilizumab in Adults Onset Still's Disease, real-world data from Japan affirmed its effectiveness and as a steroid-sparring agent @RheumNow https://t.co/jbmhEnGwXO
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Stop repeating the #ANA test!
46% of all ANA tests were repeat tests in this study. #HealthCareCost #NoUtility #ChooseWisely abst#1278 @rheumnow #ACR22 https://t.co/K7oyqJYvi9
TheDaoIndex KDAO2011 ( View Tweet)
Limited utility for using bone turnover markers in osteoporosis. Perhaps useful to assess adherence to oral therapy.
@RheumNow #ACR22 #osteoporosis https://t.co/g6f7SnOzNR
Julian Segan JulianSegan ( View Tweet)
Puechal et al RTX vs CYC induction in GPA: target trial emulation study. BVAS 0 and pred=<10mg at 6 months 73% RTX vs 40% CYC. RR 1.82[95%CI:1.22;2.73] @RheumNow #ACR22 Abstr#1084 https://t.co/6e8wutMC2H https://t.co/OpeajFVdJf
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Advancing Telemedicine in Rheumatology
'60% prefer telemedicine for routine visits and review lab results'
https://t.co/HUgoocXodE
@RheumNow #ACR22
Akhil Sood MD AkhilSoodMD ( View Tweet)